Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATAD2 in cancer: a pharmacologically challenging but tractable target

17 Nov 2017

Abstract excerpt

INTRODUCTION: ATAD2 protein is an emerging oncogene that has strongly been linked to the etiology of multiple advanced human cancers. Therapeutically, despite the fact that genetic suppression/knockdown studies have validated it as a compelling drug target for future therapeutic development, recent druggability assessment data suggest that direct targeting of ATAD2's bromodomain (BRD) may be a very challenging...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29148850
DOI: 10.1080/14728222.2018.1406921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATAD2 in cancer: a pharmacologically challenging but tractable targetPMID 29148850Read ↗

Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain InhibitorsSemantic proximity Read ↗

ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic targetSemantic proximity Read ↗

Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancersSemantic proximity Read ↗

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain InhibitorsSemantic proximity Read ↗

Disulfide bridge formation influences ligand recognition by the ATAD2 bromodomain.Semantic proximity Read ↗

BRD4 in physiology and pathology: ‘‘BET’’ on its partnersSemantic proximity Read ↗

Systematic profiling of the acetyl lysine machinery reveals a role for MAPKAPK2 in bromodomain inhibitor resistanceSemantic proximity Read ↗

The Journey of DDR1 and DDR2 Kinase Inhibitors as Rising Stars in the Fight Against CancerSemantic proximity Read ↗

Targeting bromodomain-containing proteins: research advances of drug discoverySemantic proximity Read ↗

Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53- and p38-mediated apoptotic signaling.Semantic proximity Read ↗

A non-canonical role for the ATAD2 ortholog BDF7 in nucleolar ribosome maturation and amastigote survival in <i>Leishmania mexicana</i>Semantic proximity Read ↗

Evaluation of ATAD2 As a Potential Target in Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.